TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
About Datamonitor Healthcare 3
About the Oncology pharmaceutical analysis team 3
Executive Summary 5
Scope of the analysis 5
Datamonitor insight into the hormone receptor-negative breast cancer market 5
Contributing experts 7
Related reports 7
Upcoming related reports 7
1. Introduction and Scope 10
Coverage of the Stakeholder Insight Survey 10
2. Epidemiology 11
Introduction and background 11
Key points 11
Disease definition and diagnosis criteria 12
Global variation and historical trends 12
Risk factors 15
Epidemiologic forecasting of breast cancer 17
Description of methods 21
Epidemiologic Forecast Results 23
Discussion 30
Conclusions 32
3. Disease overview 33
Introduction 33
Patient segmentation 35
4. Treatment options 39
Introduction 39
5. Treatment Trends: Stage I–III 45
Triple-negative breast cancer 45
HER-2-positive breast cancer 59
6. Treatment Trends: Stage IV and Relapse 80
Triple-negative breast cancer 80
HER-2-positive breast cancer 113
7. Future Treatment 144
Late-phase pipeline products overview 144
Future treatment scenarios 196
BIBLIOGRAPHY 201
Chapter 2. Epidemiology 201
Chapter 3. Disease Overview 207
Chapter 4. Treatment Options 209
Chapter 5. Treatment Trends: Stage I–III Breast Cancer 211
Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer 212
Chapter 7. Future Treatment 214
APPENDIX A 219
Abbreviations 219
Physician research methodology 219
Physician sample breakdown 220
Contributing experts 221
APPENDIX B 222
The survey questionnaire 222
Datamonitor consulting 276
Disclaimer 277